# Oncology Pharmaceuticals: Reproductive Toxicity Testing and Labeling Recommendations Guidance for Industry: Guidance for Industry - FDA Guidance Document Source: https://www.globalkeysolutions.net/guidances/guidance-document/oncology-pharmaceuticals-reproductive-toxicity-testing-and-labeling-recommendations-guidance-for-industry-guidance-for-industry/91713d82-572d-4f50-b440-cca500b50106 > FDA guidance document: Oncology Pharmaceuticals: Reproductive Toxicity Testing and Labeling Recommendations Guidance for Industry: Guidance for Industry. Issue date: May 10, 2019. Get complete insights and analysis. --- ## Details - Title: Oncology Pharmaceuticals: Reproductive Toxicity Testing and Labeling Recommendations Guidance for Industry: Guidance for Industry - Communication Type: Guidance Document - Product Type: drugs - Office Name: Center for Drug Evaluation and Research - Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c - Issue Date: 2019-05-10 - Last Changed: 2020-05-14 - Docket Number: FDA-2017-D-2165 ## Related Documents - [Oncology Therapeutic Radiopharmaceuticals: Nonclinical Studies and Labeling Recommendations Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/oncology-therapeutic-radiopharmaceuticals-nonclinical-studies-and-labeling-recommendations-guidance-for-industry/207c1c32-d577-4283-836d-ae7bb8e1ea92) - [Uncomplicated Urinary Tract Infections: Developing Drugs for Treatment Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/uncomplicated-urinary-tract-infections-developing-drugs-for-treatment-guidance-for-industry/c70a4ac7-4c57-4214-9174-25145ed55675) - [Osteoporosis: Nonclinical Evaluation of Drugs Intended for Treatment Guidance for Industry: Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/osteoporosis-nonclinical-evaluation-of-drugs-intended-for-treatment-guidance-for-industry-guidance-for-industry/8305ef9e-7edf-412b-bb46-28ef3a7f9493)